Oncodesign Services

The Oncodesign Services-ZoBio Group partners with biotech and biopharma drug hunters to support drug development from early discovery through preclinical candidate selection. As a science-driven research partner with deep domain expertise in oncology, immunology, and inflammation, we’re trusted by leading pharma and biotech companies to deliver complex programs, including working with cutting-edge modalities from PROTACs and RNA therapeutics to ADCs and molecular glues. Our experience also extends to specialized areas such as radiopharmaceutical development and fragment-based drug discovery, in which we have a strong track record of success. Our highly regarded teams in structural biology, medicinal chemistry, in vitro biology, imaging, and pharmacology combine rigorous scientific excellence with a nimble, partnership-first approach. Our core capabilities include- Finding and accelerating solutions for challenging and novel targets, including advanced fragment discovery and covalent library screening- Standalone studies or seamless progression from target validation, hit finding and lead optimization, through to preclinical development- Access to a comprehensive suite of research models, including advanced models such as orthotopic, PDX organoid, immuno-oncology, and endometriosis- Expertise in ADME/DMPK, PK/PD modeling, imaging, and translational biology- GLP/GCLP-compliant infrastructure with a strong regulatory track record. With a flexible business model, we offer complementary expertise to help prioritize projects, design workflows, and execute focused, target-driven campaigns. The Oncodesign Services-ZoBio Group employs ~200 experts highly skilled in early discovery research and translational pharmacology. We collaborate closely with big pharma, biotech, public research institutions, and investment groups to support the advancement of innovative therapeutic agents.